Changes in Hong Kong stocks | Xianruida Medical-B (06669) rose more than 4% Recently, Sirolimus drug-coated coronary balloon dilation catheter AcoArt Canna® registration was approved

The Zhitong Finance App learned that Xianruida Medical-B (06669) rose more than 4%. As of press release, it had risen 4.63% to HK$11.97, with a turnover of HK$6.2497 million.

^{According to the news, recently, Xianruida Medical-B issued an announcement. The Group has received approval from the China National Drug Administration for registration of the sirolimus drug-coated coronary balloon dilation catheter AcoArt Canna®. ACoArt Canna® is used for dilatation treatment of primary coronary artery bifurcation stenosis with a blood vessel diameter of ≥2.0 mm and ≤ 4.0 mm.}

^{According to reports, clinical trial results proved the efficacy and safety of ACoArt Canna® in clinical application: the main end indicators of the clinical trial were the target lesion branch blood vessel diameter stenosis rate (DS,%) shown by angiography 9 months after surgery, the D.S. in the test group using AcoArt Canna® was 30.52%, and the control group using paclitaxel drug-coated coronary balloon dilatation catheters was 33.46% at 9 months after surgery, and there was no statistical difference between the two groups;} Based on clinical safety data analysis, the test group showed no abnormal risks or events compared to the control group. The company will launch marketing activities in China in due course.